Volume 10, Number 8—August 2004
Synopsis
Vibrio vulnificus in Taiwan
Po-Ren Hsueh*
, Ching-Yih Lin†, Hung-Jen Tang†, Hsin-Chun Lee‡, Jien-Wei Liu§, Yung-Ching Liu¶, and Yin-Ching Chuang†
, Ching-Yih Lin†, Hung-Jen Tang†, Hsin-Chun Lee‡, Jien-Wei Liu§, Yung-Ching Liu¶, and Yin-Ching Chuang†
Table
Clinical characteristics of 84 patients with Vibrio vulnificus infections who were treated at five major hospitals, Taiwan, 1995–2000
| Characteristic (no. of patients for whom information was available) | No. of patients (%) |
|---|---|
| Sex (n = 84) |
|
| Male/female |
61 (72.6)/23 (27.4) |
| Age, mean/range (yr) |
60/9-87 |
| Underlying disease (n = 84)a |
|
| Chronic hepatitis B or C virus infection |
10 (11.9) |
| Liver cirrhosis |
35 (41.7) |
| Hepatitis B or C virus infection-related |
21 |
| Alcoholic |
7 |
| Hepatoma |
7 |
| Diabetes mellitus |
13 (15.5) |
| Steroid use |
10 (11.9) |
| Alcoholism |
8 ( 9.5) |
| Renal insufficiency |
6 (7.1) |
| Other malignancies |
3 (3.6) |
| None |
12 (14.3) |
| Type of infection (n =84) |
|
| Cutaneous infection |
57 (67.9) |
| Cellulitis |
15 (17.9) |
| With bacteremia |
5 |
| With septic shock |
6 |
| Necrotizing fasciitis |
42 (50.0) |
| With bacteremia |
2 |
| With septic shock |
32 |
| Primary septicemia |
20 (23.8) |
| With septic shock |
3 |
| Spontaneous bacterial peritonitis |
6 ( 7.1) |
| Meningitis |
1 ( 1.2) |
| Exposure history (n = 55) |
|
| Injury from handling marine animals (fish, crab) |
7 (12.7) |
| Preexisting skin wounds |
11 (20.0) |
| Ingestion of raw seafood |
2 ( 3.6) |
| None |
35 (63.6) |
| Initial antibiotic treatment (n = 82) |
|
| A third-generation cephalosporinb plus minocycline |
38 (46.3) |
| A first-generation cephalosporin plus an aminoglycoside |
15 (18.3) |
| Other combinationsc |
29 (35.4) |
| Surgical treatment (cutaneous lesions, n = 57) |
|
| Incision and drainage, débridement and/or fasciotomy |
43 (75.4) |
| Amputation |
6 (10.5) |
| Outcome |
|
| Survived |
57 (67.9) |
| Died |
25 (29.8) |
| Unknown | 2 ( 2.4) |
aPatients might have more than two underlying diseases.
bInclude ceftazidime, cefotaxime, ceftriaxone, and moxalactam.
cInclude a penicillin or a first-generation cephalosporin plus an aminoglycoside or minocycline.
Page created: March 03, 2011
Page updated: March 03, 2011
Page reviewed: March 03, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.